BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 26043110)

  • 21. Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.
    Choi JY; Han HH; Kim YT; Lee JH; Kim BG; Kang S; Cho NH
    Yonsei Med J; 2017 Jan; 58(1):59-66. PubMed ID: 27873496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
    Lapke N; Chen CH; Chang TC; Chao A; Lu YJ; Lai CH; Tan KT; Chen HC; Lu HY; Chen SJ
    BMC Cancer; 2021 May; 21(1):499. PubMed ID: 33947352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway.
    Murayama-Hosokawa S; Oda K; Nakagawa S; Ishikawa S; Yamamoto S; Shoji K; Ikeda Y; Uehara Y; Fukayama M; McCormick F; Yano T; Taketani Y; Aburatani H
    Oncogene; 2010 Apr; 29(13):1897-908. PubMed ID: 20062086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allelotype analysis of common epithelial ovarian cancers with special reference to comparison between clear cell adenocarcinoma with other histological types.
    Okada S; Tsuda H; Takarabe T; Yoshikawa H; Taketani Y; Hirohashi S
    Jpn J Cancer Res; 2002 Jul; 93(7):798-806. PubMed ID: 12149146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integration of transcript expression, copy number and LOH analysis of infiltrating ductal carcinoma of the breast.
    Hawthorn L; Luce J; Stein L; Rothschild J
    BMC Cancer; 2010 Aug; 10():460. PubMed ID: 20799942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary.
    Köbel M; Kalloger SE; Carrick J; Huntsman D; Asad H; Oliva E; Ewanowich CA; Soslow RA; Gilks CB
    Am J Surg Pathol; 2009 Jan; 33(1):14-21. PubMed ID: 18830127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma.
    Tamura R; Yoshihara K; Matsuo K; Yachida N; Miyoshi A; Takahashi K; Sugino K; Yamaguchi M; Mori Y; Suda K; Ishiguro T; Okuda S; Motoyama T; Nakaoka H; Kikuchi A; Ueda Y; Inoue I; Enomoto T
    Gynecol Oncol; 2021 Nov; 163(2):327-333. PubMed ID: 34452748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases.
    Han G; Gilks CB; Leung S; Ewanowich CA; Irving JA; Longacre TA; Soslow RA
    Am J Surg Pathol; 2008 Jul; 32(7):955-64. PubMed ID: 18460981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of heterozygosity on chromosome 6q27 and p53 mutations in epithelial ovarian cancer.
    Suzuki M; Saito S; Saga Y; Ohwada M; Sato I
    Med Oncol; 1998 Jul; 15(2):119-23. PubMed ID: 9789220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
    Rzepecka IK; Szafron L; Stys A; Bujko M; Plisiecka-Halasa J; Madry R; Osuch B; Markowska J; Bidzinski M; Kupryjanczyk J
    Cancer Genet; 2012 Mar; 205(3):94-100. PubMed ID: 22469508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Annexin IV is differentially expressed in clear cell carcinoma of the ovary.
    Miao Y; Cai B; Liu L; Yang Y; Wan X
    Int J Gynecol Cancer; 2009 Dec; 19(9):1545-9. PubMed ID: 19955935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
    Willner J; Wurz K; Allison KH; Galic V; Garcia RL; Goff BA; Swisher EM
    Hum Pathol; 2007 Apr; 38(4):607-13. PubMed ID: 17258789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
    Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
    Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1beta expression.
    Kato N; Motoyama T
    Histopathology; 2008 May; 52(6):682-8. PubMed ID: 18393978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [An approach to early genetic alterations in precancerous cells].
    Sato N; Nishida M; Noguchi M
    Hum Cell; 2000 Sep; 13(3):103-8. PubMed ID: 11197771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas.
    Benetkiewicz M; Wang Y; Schaner M; Wang P; Mantripragada KK; Buckley PG; Kristensen G; Børresen-Dale AL; Dumanski JP
    Genes Chromosomes Cancer; 2005 Mar; 42(3):228-37. PubMed ID: 15578687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
    Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
    Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
    Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
    Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas.
    Schwartz DR; Kardia SL; Shedden KA; Kuick R; Michailidis G; Taylor JM; Misek DE; Wu R; Zhai Y; Darrah DM; Reed H; Ellenson LH; Giordano TJ; Fearon ER; Hanash SM; Cho KR
    Cancer Res; 2002 Aug; 62(16):4722-9. PubMed ID: 12183431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.